Metabolomic Diagnostic raises €750k seed investment
From siliconrepublic.ie, 3rd Jan 2014
Metabolomic Diagnostics, is pleased to announce that it has secured €750,000 ($1.03m) in venture funding through a syndicate of investors including SOS ventures Ireland Fund, AIB Seed Capital Fund and Enterprise Ireland.
Metabolomic Diagnostic's innovative solution has the potential to revolutionise pre-natal care with its breakthrough blood test "PrePsia" for early detection of women at high risk of developing pre-eclampsia during their pregnancy. The product has a real chance of saving lives.
CEO and Serial entrepreneur Charles Garvey told Silicon Republic:
"Our PrePsia solution could potentially become a standard part of prenatal care globally. We are delighted to be working with lead investor, SOSventures Ireland Fund along with the AIB Seed Capital Fund and Enterprise Ireland."
Metabolomic Diagnostics' study called IMPROvED, has received €6m in European FP7 funding. One of Garvey's previous startups, Horizon Technology Group was floated on the London and Dublin stock markets at a valuation of stg£90m, and was subsequently acquired by Avnet.
